Investigating the role of cardiac exosomes in heart injury from reduced blood flow
Official title: Cardiac Exosomes in myocardial Ischemic injury
Funded at Johns Hopkins University · NIH-10984767 · Data updated 2026-11-12
This study is looking at tiny particles released by heart cells to see how they might affect heart damage when blood flow is reduced, and it's for patients having heart surgery to help find new ways to treat heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $633,180 |
| NIH project number | 7R01HL150401-05 |
| Project ID | NIH-10984767 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing cardiac surgery who experience myocardial ischemia.
✕Less likely to help
Patients with stable ischemic heart disease who are not undergoing surgical intervention may not benefit from this research.
What this research studies
This research focuses on understanding how cardiac exosomes, which are small vesicles released by heart cells, contribute to the injury caused by reduced blood flow during ischemic heart disease. By analyzing samples from patients undergoing cardiac surgery, the study aims to uncover the biological processes involved in heart cell communication and the potential role of noncoding RNAs in these processes. The research utilizes advanced techniques to examine the genetic and molecular changes in heart cells during ischemia, providing insights into new therapeutic approaches and biomarkers for heart disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments and diagnostic tools for patients suffering from ischemic heart disease.
How similar studies have gone: Previous research has shown promise in using extracellular vesicles as biomarkers and therapeutic agents in various conditions, indicating a potential for success in this novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Muehlschlegel, Jochen Daniel — Johns Hopkins University
- Study coordinator: Muehlschlegel, Jochen Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.